Clene Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 4, 2026, disclosing condensed consolidated financial statements and management discussion for the third quarter.

Key Highlights

  • Total assets: According to the filing, Clene reported total assets of $22.157 million as of September 30, 2026, up from $18.131 million at December 31, 2025.
  • Total liabilities: The filing disclosed total liabilities of $36.965 million as of September 30, 2026, compared to $35.723 million at December 31, 2025.
  • Accumulated deficit: The company reported an accumulated deficit of $325.896 million as of September 30, 2026, versus $308.296 million at December 31, 2025.
  • Cash position: Cash and cash equivalents stood at $9.887 million as of September 30, 2026, compared to $5.189 million at December 31, 2025.
  • Shares outstanding: The filing states 14,213,981 shares were issued and outstanding at September 30, 2026, and 14,400,175 shares were outstanding as of November 2, 2026.
  • Common stock warrant liabilities: These liabilities totaled $8.644 million at September 30, 2026, up from $5.063 million at December 31, 2025.

Clene Inc. Financial Position as of September 30, 2026

Clene Inc. (NASDAQ:CLNN), a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Salt Lake City, Utah, filed its quarterly report covering the period ended September 30, 2026. According to the filing, the company operates under a stockholders' deficit, with additional paid-in capital of $310.860 million at September 30, 2026, compared to $290.531 million at December 31, 2025. The common stock carries a par value of $0.0001, with 600,000,000 shares authorized under the company's charter.

The filing disclosed that current liabilities reached $17.114 million at September 30, 2026, up from $10.776 million at December 31, 2025. Convertible notes payable, current portion, rose to $7.980 million from $2.378 million over the same period. Notes payable, current portion, increased to $4.974 million from $1.696 million. Non-current convertible notes payable declined to $5.295 million from $9.800 million, while non-current notes payable decreased to $0.964 million from $3.741 million, reflecting reclassifications between current and non-current portions.

The filing also identified derivative liabilities of $2.345 million and operating lease right-of-use assets of $2.587 million as of September 30, 2026. Accrued liabilities fell to $2.510 million from $5.002 million at year-end 2025. The company noted forward-looking statements regarding its ability to continue as a going concern, plans to raise additional funding, and the clinical development of its drug candidates, all of which are subject to risks and uncertainties described in the filing's cautionary language.

What Was Disclosed

Clene Inc. submitted its September 30, 2026 Form 10-Q on November 4, 2026, reporting total assets of $22.157 million, total liabilities of $36.965 million, an accumulated deficit of $325.896 million, and 14,213,981 shares issued and outstanding at quarter end.